Investors Hangout Stock Message Boards Logo
  • Home
  • Mailbox
  • Boards
  • Favorites
  • Whats Hot!
  • Login - Join Now!
CytoDyn Inc CYDY
(Total Views: 1532)
Posted On: 07/15/2025 1:02:37 AM
Post# of 155780
Posted By: My69z
Date: 26-May-2021
Protocol Number: CD15_COVID-19
Version: 5.0

That is the Long Hauler 190 page protocol.

Page 68:
8.2.3. Exploratory Outcome Measures (Endpoints)

*Change from baseline in CD4+ and CD8+ T cell count on Days 28 and 56
_____
Jumo to the Long Hauler trial in florida:

Change From Baseline in CD4+ and CD8+ T Cell Count on Days 28 and 56.

We did not report the CD4+ and CD8+ T Cells in the LH trial final results.

Due to being Exploratory ?

Why create the CCR5 RO Assay, & not use it in the LH trial ?

My bet is the obvious:
They did & post Amarex settlement, now also have the CD4+ T cells data of Baseline to days 28 & 56.

No press releases due to still waiting on RECOVER-LC acceptance / rejection decision.

Either way, Cytodyn has a CCR5 RO Assay to measure CD4+ T Cells in any applicable trial....

https://clinicaltrials.gov/study/NCT04678830

https://pmc.ncbi.nlm.nih.gov/articles/PMC8640501/













(7)
(1)









  • New Post - Investors HangoutNew Post

  • Public Reply - Investors HangoutPublic Reply

  • Private Reply - Investors HangoutPrivate Reply

  • Board - Investors HangoutBoard

  • More - Investors HangoutMore

  • Keep Post - Investors HangoutKeep Post
  • Report Post - Investors HangoutReport Post
  • Home - Investors HangoutHome
  • Mailbox - Investors HangoutMailbox
  • Boards - Investors HangoutBoards
  • Favorites - Investors HangoutFavorites
  • Whats Hot! - Investors HangoutWhats Hot!
  • Settings - Investors HangoutSettings
  • Login - Investors HangoutLogin
  • Live Site - Investors HangoutLive Site